FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1560654611> ?p ?o ?g. }

• W1560654611 endingPage "46" @default.
• W1560654611 startingPage "36" @default.
• W1560654611 abstract "Topical steroids are used for more than 50 years to treat mild-to-moderate plaque psoriasis. The purpose of this systematic review was to evaluate the efficacy but also the optimal modalities of administration of topical corticosteroids in psoriasis i.e. influence of steroid potency on clinical response, putative impact of topical formulation, occlusion procedure, rate of application to control the initial response and the potential interest of a maintenance treatment to prolong psoriasis clearance.A systematic search was performed between 1980 and January 2011 in Medline, Embase and Cochrane databases (English and French language, adults), using the keywords 'psoriasis'/exp/mj AND 'corticosteroid'/exp/mj. To analyse response across studies, three levels of response were categorized depending on the data available in studies: percentage of patients who achieved more than 50%, 75% or 90% improvement of initial psoriasis severity.From an initial selection of 1269 references, 1166 references were excluded on reading the title or the abstract and 32 on reading the article and 71 were finally retained and analysed. Fifty randomized controlled trials (RCT) assessing topical steroids in the initial treatment of mild-to-severe psoriasis body plaque psoriasis were retained: 40 were parallel-group studies and 10 were within-patient studies. Treatment duration was mostly 4 weeks. Sample size varied from 30 to 1 603 patients. Outcome measures to assess efficacy were highly variable. A total of 30-90% patients across parallel group studies experienced more than 50% of initial mild-to-severe psoriasis improvement while from 7% to 85% experienced more than 75% improvement and from 5% to 85% experienced at least 90% of improvement. The success rate in the within-patient studies varied from 10% to 70%. Eighteen RCT were performed in scalp psoriasis: 16 were parallel-group and two were within-patient studies, with a treatment follow-up time from 2 weeks to 6 months, enrolling 42-1417 patients. A total from 40% to 75% patients across studies experienced more than 75% of initial scalp psoriasis improvement and from 43% to 90% experienced more than 90% initial psoriasis improvement. Only three RCT studies evaluated topical steroids as a maintenance treatment for body psoriasis and one for scalp lesions. Despite heterogeneity in treatment schedule, topical steroid intermittent maintenance treatment was shown to prolong remission. The literature analysis did not provide with high evidence-based quality data on the role of formulation, topical steroid potency, number of applications per day to obtain the highest rate of success excepting occlusion dressing which provided with additional benefit.The clinical development of topical steroids in psoriasis did not follow state of the art modern methodology. Treatment success appears to be highly variable across studies. Maintenance intermittent treatment appears to be useful to prolong remission. Recommendations concerning topical steroids treatment modalities in plaque psoriasis should be mostly based on expert opinion." @default.
• W1560654611 created "2016-06-24" @default.
• W1560654611 creator A5000455992 @default.
• W1560654611 creator A5020129995 @default.
• W1560654611 creator A5032287704 @default.
• W1560654611 creator A5044024585 @default.
• W1560654611 creator A5048575128 @default.
• W1560654611 creator A5050410393 @default.
• W1560654611 creator A5050985511 @default.
• W1560654611 creator A5052126855 @default.
• W1560654611 creator A5054896012 @default.
• W1560654611 creator A5065536566 @default.
• W1560654611 creator A5071179145 @default.
• W1560654611 creator A5075769077 @default.
• W1560654611 creator A5084151252 @default.
• W1560654611 creator A5087331944 @default.
• W1560654611 creator A5087905603 @default.
• W1560654611 date "2012-04-18" @default.
• W1560654611 modified "2023-10-03" @default.
• W1560654611 title "Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities" @default.
• W1560654611 cites W1578446396 @default.
• W1560654611 cites W1727368315 @default.
• W1560654611 cites W1940145814 @default.
• W1560654611 cites W1970848707 @default.
• W1560654611 cites W1972552122 @default.
• W1560654611 cites W1974724279 @default.
• W1560654611 cites W1977180696 @default.
• W1560654611 cites W1981217350 @default.
• W1560654611 cites W1987310521 @default.
• W1560654611 cites W1994129835 @default.
• W1560654611 cites W1997949215 @default.
• W1560654611 cites W2001958615 @default.
• W1560654611 cites W2003921145 @default.
• W1560654611 cites W2008791869 @default.
• W1560654611 cites W2024542142 @default.
• W1560654611 cites W2025490383 @default.
• W1560654611 cites W2026674216 @default.
• W1560654611 cites W2033642983 @default.
• W1560654611 cites W2047650650 @default.
• W1560654611 cites W2051469935 @default.
• W1560654611 cites W2052443247 @default.
• W1560654611 cites W2056996122 @default.
• W1560654611 cites W2057485779 @default.
• W1560654611 cites W2068625972 @default.
• W1560654611 cites W2073269393 @default.
• W1560654611 cites W2075016651 @default.
• W1560654611 cites W2075258331 @default.
• W1560654611 cites W2078424507 @default.
• W1560654611 cites W2083822655 @default.
• W1560654611 cites W2087281658 @default.
• W1560654611 cites W2091618194 @default.
• W1560654611 cites W2092916329 @default.
• W1560654611 cites W2098625488 @default.
• W1560654611 cites W2099719148 @default.
• W1560654611 cites W2100526323 @default.
• W1560654611 cites W2108816834 @default.
• W1560654611 cites W2119757529 @default.
• W1560654611 cites W2120827557 @default.
• W1560654611 cites W2124518713 @default.
• W1560654611 cites W2125379679 @default.
• W1560654611 cites W2126880257 @default.
• W1560654611 cites W2131364029 @default.
• W1560654611 cites W2136420317 @default.
• W1560654611 cites W2137391335 @default.
• W1560654611 cites W2144109763 @default.
• W1560654611 cites W2144150076 @default.
• W1560654611 cites W2146663751 @default.
• W1560654611 cites W2154470408 @default.
• W1560654611 cites W2157557681 @default.
• W1560654611 cites W2163031644 @default.
• W1560654611 cites W2163765792 @default.
• W1560654611 cites W2165992061 @default.
• W1560654611 cites W2166307479 @default.
• W1560654611 cites W2171805769 @default.
• W1560654611 cites W2413872217 @default.
• W1560654611 cites W3176789243 @default.
• W1560654611 cites W4210998242 @default.
• W1560654611 cites W4251313733 @default.
• W1560654611 cites W74634963 @default.
• W1560654611 doi "https://doi.org/10.1111/j.1468-3083.2012.04522.x" @default.
• W1560654611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22512679" @default.
• W1560654611 hasPublicationYear "2012" @default.
• W1560654611 type Work @default.
• W1560654611 sameAs 1560654611 @default.
• W1560654611 citedByCount "27" @default.
• W1560654611 countsByYear W15606546112012 @default.
• W1560654611 countsByYear W15606546112013 @default.
• W1560654611 countsByYear W15606546112014 @default.
• W1560654611 countsByYear W15606546112016 @default.
• W1560654611 countsByYear W15606546112017 @default.
• W1560654611 countsByYear W15606546112018 @default.
• W1560654611 countsByYear W15606546112019 @default.
• W1560654611 countsByYear W15606546112020 @default.
• W1560654611 countsByYear W15606546112021 @default.
• W1560654611 countsByYear W15606546112022 @default.
• W1560654611 countsByYear W15606546112023 @default.
• W1560654611 crossrefType "journal-article" @default.
• W1560654611 hasAuthorship W1560654611A5000455992 @default.

• next